<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161397">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846195</url>
  </required_header>
  <id_info>
    <org_study_id>Zynex500</org_study_id>
    <nct_id>NCT01846195</nct_id>
  </id_info>
  <brief_title>Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw</brief_title>
  <official_title>Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Adult Patients During a Blood Draw</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zynex Monitoring Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DTarget</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zynex Monitoring Solutions</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive monitoring to measure changes in blood volume.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Detect by non-invasive monitoring a change in blood volume during a whole blood draw</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety to determine non-serious unanticipated adverse device events (UADEs)</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is a non-significant research and development study. Anticipated adverse effects include localized skin irritation from sensors or mild discomfort from lying supine for a prolonged period of time. All UADEs will be monitored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>no blood draw</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>CM 1500 with no blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blood draw</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CM 1500 with blood draw</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CM 1500</intervention_name>
    <arm_group_label>no blood draw</arm_group_label>
    <arm_group_label>blood draw</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Between 18-35 years of age

          -  Weight between 130-200 pounds

        Exclusion Criteria:

          -  Known cardiac disease

          -  Recent caffeine intake

          -  Tobacco use in the (4) hours prior to screening

          -  Infection

          -  Pregnancy

          -  Hemoglobin &lt;13.5 g/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ziegler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Ziegler, MD</last_name>
    <phone>801-266-0815</phone>
    <email>John.Ziegler@premier-research.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Premier Research Group</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Gray</last_name>
      <phone>801-266-0815</phone>
      <email>Russell.Gray@premier-research.com</email>
    </contact>
    <investigator>
      <last_name>John Ziegler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
